Innova Biosciences Appoints Steve Howell as Non-Executive Director
Cambridge, UK, 01 February 2016: Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, today announced the appointment of Professor Steve Howell to the Board of Directors.
Steve has over 20 years of experience building and growing life science enterprises, including founding life science investment company Innova Partnerships in 2006. Prior to this he was Director of Business Development at Alere Inc, and Research Director at Unipath Ltd, after joining Unilever Plc. Steve is currently a non-executive director of Reminova Ltd and Relaymed. He is visiting Professor of Commercial Innovation at Kings College London and also advises the Scottish and Irish governments on high growth businesses and life science strategy.
Tim Bernard, Chairman of the Board at Innova Biosciences, commented: “We are delighted to welcome Steve to the Board of Directors. His knowledge and experience will be a valuable addition to the company as we continue to expand.
Professor Howell said: “Innova Biosciences’ world leading bioconjugation technology business is backed by a team of dedicated executives, scientists and customer service personnel. I am very pleased to be joining the Board, to help lead Innova through its next stages of development.”
Image: Professor Steve Howell
For a high-resolution image please contact Zyme Communications
Katie Odgaard, Zyme Communications
Phone: +44 (0)7787 502 947
About Innova Biosciences Limited
Innova Biosciences are world leading experts in easy-to-use, cutting-edge bioconjugation technologies and services. The Company has the flexibility to support scientists from academia through to commercial manufacturing, developing and supplying reagent products to make science easier, both off-the shelf and to customer specification. Innova’s products are based on its antibody and protein labeling, nanoparticle, oligonucleotide labeling, and phosphate detection enzyme assay technologies.
All of Innova Biosciences’ product ranges are of the highest quality and are designed to streamline R&D and manufacturing processes, whilst also reducing overall project costs by cutting costs associated with e.g. material waste, in-house equipment, and staff time, providing increased return on investment compared to traditional methods.
Innova Biosciences’ ever expanding portfolio, including the Lightning-Link®, InnovaCoat® and Thunder-Link® brands, is available to research laboratories, pharmaceutical, biotechnology and diagnostic companies worldwide.
Innova Biosciences is a privately held company, and was founded in 2002.